AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04435353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VibroLUNG
Description: Lungs intensive therapy
Study NCT01184183 — intervention group
Intervention type: PROCEDURE
Intervention: Comparing Accuseal Vs. Bovine Pericardial in CEA
Description: Accuseal patch - The Goretex Company has since designed a new patch, the Accuseal, which is marketed as decreasing the intra-operative time (i.e, having a short hemostasis time) without affecting the perioperative stroke rate.~Bovine Pericardial patch - The Bovine Pericardial patch has been used for nearly two decades, since the late 1990s. However, studies based on retrospective review of data in which patients received the Bovine Pericardial patch, reported the clinical outcomes post-operative stroke, death, time to hemostasis and recurrent restenosis.
Study NCT01392794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral, without water
Study NCT00796653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high doses on efficacy and safety in COPD patients
Study NCT00796653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
Study NCT00796653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
Study NCT00315562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid endarterectomy
Study NCT00315562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carotid endarterectomy
Study NCT02436447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.
Study NCT02436447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.
Study NCT02436447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment
Study NCT02436447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment
Study NCT02308475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatom Force CT Scanner
Description: Dynamic CT perfusion of the heart
Study NCT03023150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning
Study NCT03023150 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT01776190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA1 radiation treatment
Study NCT02570009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TEAMS (Talking about Eating, Activity, Mutual Support)
Study NCT02570009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Need Support Training
Study NCT06456918 — intervention group
Intervention type: PROCEDURE
Intervention: Quality of Recovery 15 questionnaire
Description: return to daily life after surgery according to the patient's baseline or social norms
Study NCT01346735 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00879918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated nicotine and cotinine
Description: used as a marker for pharmacokinetic studies
Study NCT04019951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ca-propionate 1 g
Description: 1 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
Study NCT04019951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ca-propionate 3 g
Description: 3 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
Study NCT04019951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.6 g of cellulose will be mixed in 203 mL of a standardized liquid breakfast
Study NCT03217539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Imaging
Study NCT00697476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan, vorinostat
Description: Phase I study: vorinostat will be administered daily for a number of days per cycle variable from 7 to 14 according to the level of dose escalation; topotecan will be administered I.V. for 5 consecutive days every 3 weeks.~Phase II study: Patients will receive treatment at the recommended dose established by phase I part of the trial, for a maximum of 6 cycles or until disease progression, unacceptable toxicity or patient's refusal.
Study NCT03708458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indomethacin suppository
Description: the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
Study NCT03708458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
Study NCT03575234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03575234 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IRX-2
Description: Given SC
Study NCT03575234 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03575234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo surgery
Study NCT00857103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHOICE
Description: Use of Choice support system as preparation for patient consultations
Study NCT01401803 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dysport
Description: Patients entering will be based on gender and assessment of the glabella region (including the corrugators, procerus, and medial frontalis muscles). Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large). Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ and female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region. On (Day0) patients will be treated with Dysport™ 10 to 20 units bilaterally to the depressor component of the orbicularis. The dosing for patients will be based on assessment of orbicularis muscle mass. Patients will receive .05 mL to 0.1 mL (10 or 20 units) in two equally divided doses of Dysport™. Muscle mass will not be graded based upon gender for this region.
Study NCT02045472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS410
Study NCT02045472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00800514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amantadine
Description: amantadine 100 mg twice daily
Study NCT03087552 — intervention group
Intervention type: PROCEDURE
Intervention: Transradial balloon aortic valvuloplasty
Description: Mini-invasive balloon aortic valvuloplasty consisting in transradial access
Study NCT03087552 — intervention group
Intervention type: PROCEDURE
Intervention: Transradial balloon aortic valvuloplasty
Description: Rapid pacing using the 0.035-in. retrograde left ventricular support wire
Study NCT03016637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SharkCore (TM) FNB Exchange System
Study NCT05186155 — intervention group
Intervention type: PROCEDURE
Intervention: Severe ROP
Description: The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
Study NCT01744821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arm A: Vitamin D3 Group
Study NCT01744821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02997670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithmic Cardiac Resynchronisation Therapy Optimisation
Description: Use of a computer algorithm to run through multiple combinations of pacing options in patients who have a Cardiac resynchronisation pacemaker with defibrillator where a quadripolar lead has been implanted. These quadripolar leads offer extra options for pacing locations across the heart, as well as for different combinations and sequences of pacing stimuli.
Study NCT01060176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT01060176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Study NCT02751905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered orally as specified in treatment arm
Study NCT00778180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide 80 mg tablets
Study NCT00778180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide 80 mg tablets
Study NCT00590473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interstim
Description: Unilateral vs. Bilateral Placement of Interstim IPG
Study NCT04211896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
Study NCT04211896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given at a dose of 240 mg every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
Study NCT02859116 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of digestive tissues
Description: The surgeon will resect a sample (approximately 1-5 cm x 1-5 cm) of healthy tissue from the distal margins of the segment and at least 4 cm from the diseased area. The specimen for research will be obtained from the tissue that would ordinarily be removed during surgery.The tissue collected for our research purposes will be only remnant tissue which is discarded by the surgeon during the surgical intervention and has no diagnostic clinical value.
Study NCT03695588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: Ultrasound guided Quadratus Lumborum block using a posterior approach. (QLB 2)
Study NCT03695588 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham QLB
Description: Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle.
Study NCT01355367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat, BAYA1040)
Description: BAYA1040 CR 40mg BID
Study NCT00757900 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MUTAGRIP
Description: Purified polyvalent vaccine for active immunisation against influenza.The vaccine is an inactivated split virus mixture of different group A and B viral strains. One 0.5 ml dose, intramuscular route.
Study NCT04094480 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polymeric non absorbable clips
Description: a method to secure appendicular stump
Study NCT04094480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: endoloops
Description: a method to secure appendicular stump
Study NCT01279993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kerato refractive Surgery
Description: This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
Study NCT04469283 — intervention group
Intervention type: OTHER
Intervention: caffeine and movement disorders
Description: Caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
Study NCT04017455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 3 cycles of atezolizumab 840 mg
Study NCT04017455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 3 cycles of bevacizumab 5mg/kg
Study NCT01931605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic arterial embolization using BeadBlock (Terumo)
Description: Selective Prostatic arterial embolization using BeadBlock (Terumo)particuls
Study NCT00520000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: standard dose of area under the curve (AUC) AUC of 6 in all arms
Study NCT00520000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: standard dose of area under the curve (AUC) AUC of 6 in all arms
Study NCT00520000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abraxane
Description: 75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle
Study NCT00520000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 180mg/m2 - 340mg/m2, repeated every 21 days
Study NCT00520000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
Study NCT04412187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-GE-180 PET
Description: serial \[18F\]-GE-180 PET imaging to assess microglia activation
Study NCT04412187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3T MRI
Description: serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness
Study NCT04412187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: immune cell profiling in blood
Description: Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.
Study NCT02210754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)
Description: electronic cigarettes
Study NCT02210754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)
Description: electronic cigarettes
Study NCT02210754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)
Description: electronic cigarettes
Study NCT02210754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)
Description: electronic cigarettes
Study NCT02210754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)
Description: electronic cigarettes
Study NCT02210754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)
Description: electronic cigarettes
Study NCT02210754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)
Description: electronic cigarettes
Study NCT02210754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)
Description: electronic cigarettes
Study NCT02210754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)
Description: electronic cigarettes
Study NCT02210754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)
Description: electronic cigarettes
Study NCT02210754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marlboro Cigarette
Description: cigarettes
Study NCT04213131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stem cell transplantation
Description: The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.
Study NCT04213131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.
Study NCT00687518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Intravenous injection of 50 U/kg of erythropoietin
Study NCT00687518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection of equivalent volume of saline serum
Study NCT02826473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BRAINCHECK
Description: Subjects of the Intervention-Group will undergo a brief cognitive assessment, using the BRAINCHECK, during hospital admission assessments. Subjects with positive results will then be referred to a Memory Clinic undergoing subsequent interdisciplinary comprehensive diagnostic examinations. Patients with established diagnosis will be invited to counselling services of the Alzheimer Association (providing social counselling).
Study NCT04569344 — intervention group
Intervention type: OTHER
Intervention: Laboratory test positive for SARS-CoV-2 virus
Description: Exposure/intervention: diagnosis of Covid-19, defined as positive laboratory test for SARS-CoV-2
Study NCT01908244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Pentatonic music
Study NCT02194075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvoxamine+Methylphenidate hydrochloride
Study NCT02194075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvoxamine+sugar pill
Study NCT02293499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PLASMA
Description: A structured asthma self-management manual (Let's Talk about Asthma \[LTAA\],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site.
Study NCT04924491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous thyTreg
Description: Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
Study NCT02361931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A hydrogel containing erythropoietin
Description: Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. RMD-G1 applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
Study NCT02361931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogel (as a part of SOC)
Description: Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. Hydrogel applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
Study NCT02329288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Study NCT02329288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03527602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foraminal enlargement
Description: After determining the working length, a rotary file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
Study NCT05051839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant surgery and restoration
Description: Implants with two different transmucosal neck configuration are placed.
Study NCT03117127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
Study NCT03117127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites